Lifestyle physical activity counselling for in-patients with major depressive disorder

Conditions

Depression Mental and Behavioural Disorders Major depressive disorder (MDD)

Kreppke JN, Cody R, Beck J, Brand S, Donath L, Eckert A, Faude O, Hatzinger M, Imboden C, Lang UE, Ludyga S, Mans S, Mikoteit T, Oswald A, Schweinfurth-Keck N, Holsboer-Trachsler E, Zahner L, Gerber M.

2024-03-234 citations

10.1038/s41398-024-02885-0

An implementation evaluation of the physical activity counseling for in-patients with major depressive disorder (PACINPAT) intervention: a randomized controlled trial.

Cody R, Kreppke JN, Fischer X, Faude O, Beck J, Brand S, Hatzinger M, Imboden C, Kügerl N, Lang UE, Mans S, Maurer R, Mikoteit T, Oswald A, Rhodius LS, Schweinfurth N, Wechsler L, Gerber M.

2023-05-043 citations

10.1186/s12888-023-04834-5

Short-term outcomes of physical activity counseling in in-patients with Major Depressive Disorder: Results from the PACINPAT randomized controlled trial

C. Robyn, Johannes Beck, Serge Brand, Lars Donath, Oliver Faude et al. (16 authors)

Frontiers in Psychiatry2023-01-186 citations

10.3389/fpsyt.2022.1045158

Depression severity and psychosocial determinants of physical activity behavior in in-patients with major depressive disorders

C. Robyn, Johannes Beck, Serge Brand, Lars Donath, Anne Eckert et al. (19 authors)

Psychology of sport and exercise2022-09-1513 citations

10.1016/j.psychsport.2022.102294

The experience of a physical activity counseling intervention among people with major depression within the PACINPAT trial – A reflexive thematic analysis

C. Robyn, Michael Cronquist Christensen, Jan-Niklas Kreppke, Oliver Faude, Markus Gerber et al. (6 authors)

Mental health and physical activity2022-07-1812 citations

10.1016/j.mhpa.2022.100464

The impact of lifestyle Physical Activity Counselling in IN-PATients with major depressive disorders on physical activity, cardiorespiratory fitness, depression, and cardiovascular health risk markers: study protocol for a randomized controlled trial.

Gerber M, Beck J, Brand S, Cody R, Donath L, Eckert A, Faude O, Fischer X, Hatzinger M, Holsboer-Trachsler E, Imboden C, Lang U, Mans S, Mikoteit T, Oswald A, Pühse U, Rey S, Schreiner AK, Schweinfurth N, Spitzer U, Zahner L.

2019-06-2026 citations

10.1186/s13063-019-3468-3

Interventions

Patients will be randomly assigned (stratified by age, gender, and depression severity) to an extended personalised physical activity and exercise counselling program (intervention group) or to genera

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years 2. Major depressive disorders according to ICD-10 diagnostic criteria (F31 type II, F32 or F33) 3. 17-item Hamilton Rating Scale for Depression (HAMD17) score =17 (moderate depression) 4. Beck's Depression Inventory II (BDI-II) score =17 (borderline clinical depression) 5. Currently not meeting the American College of Sports Medicine's physical activity recommendations (International Physical Activity Questionnaire (IPAQ) <150 minutes/week of moderate-to-vigorous physical activity) 6. Read and signed written informed consent 7. Ability to read and speak German

Exclusion criteria

Exclusion criteria: 1. History of bipolar disorder type I (F31 type I) 2. History of schizophrenia or schizoaffective disorder 3. Current active alcohol or drug abuse or dependence 4. Pathological electrocardiogram (ECG) 5. Any significant medical condition that contraindicates safe participation in physical activity 6. Pregnancy or breastfeeding 7. Active suicidal intent 8. Evidence of significant cardiovascular, neuromuscular or endocrine disorders limiting regular physical activity as per American College of Sports Medicine absolute contraindications to exercise

Design outcomes

Primary

Measure	Time frame
1. Objective physical activity, assessed using an Actigraph accelerometer for a seven day period with a sampling epoch of 10 seconds. Time spent in moderate physical activity and vigorous physical activity will be determined based on the accelerometer counts and the ActiLife® computer software. Only days with at least 13 hours of wear time will be considered as a valid measure of daily activity. Participants will need at least five valid days, = 4 weekdays and = 1 a weekend day, for the data to be included in the data analyses. This will be assessed at the baseline (1-2 weeks after hospitalisation), 6 weeks after hospitalisation and at the follow-up (12 months after hospitalisation) 2. Physical activities during which the accelerometer cannot be worn (i.e. swimming), assessed using a non-wear time sheet	—

Measure

Time frame

1. Objective physical activity, assessed using an Actigraph accelerometer for a seven day period with a sampling epoch of 10 seconds. Time spent in moderate physical activity and vigorous physical activity will be determined based on the accelerometer counts and the ActiLife® computer software. Only days with at least 13 hours of wear time will be considered as a valid measure of daily activity. Participants will need at least five valid days, = 4 weekdays and = 1 a weekend day, for the data to be included in the data analyses. This will be assessed at the baseline (1-2 weeks after hospitalisation), 6 weeks after hospitalisation and at the follow-up (12 months after hospitalisation) 2. Physical activities during which the accelerometer cannot be worn (i.e. swimming), assessed using a non-wear time sheet

—

Secondary

Measure	Time frame
The following will be assessed at the baseline (1-2 weeks after hospitalisation), 6 weeks after hospitalisation and at the follow-up (12 months after hospitalisation): 1. Self-reported physical activity, assessed using the Simple Physical Activity Questionnaire (SIMPAQ) 2. Cardiorespiratory fitness, assessed using the Åstrand indirect test of maximal oxygen uptake (VO2max) 3. Autonomic function, assessed using electrocardiography (ECG) 4. Cognitive and social determinants of exercise, assessed using various validated questionnaires: 4.1. 1-item proxy for perceived fitness 4.2. 3 items regarding exercise-related self-efficacy 4.3. 16 items regarding exercise-related outcome expectancies 4.4. 1 item regarding exercise intention 4.5. 12 item SSK-Scale for self-concordance 4.6. 10 items regarding action and coping planning 4.7. 19 items regarding perceived exercise barriers 4.8. 7 items regarding exercise-related social support 5. Depression severity, assessed using: 5.1. Hamilton Rating Scale for Depression 17-item (HAMD17) 5.2. Beck Depression Inventory (BDI) 6. Self-perceived physical and psychological health, assessed using the Medical Outcomes Study 12-item Short Form Health Survey (SF-12) 7. Insomnia symptoms, assessed using the 7-item Insomnia Severity Index (ISI) 8. Cognitive function, assessed using the Test of Attentional Performance 9. Cardiovascular health risk markers: 9.1. Blood pressure, assessed using an Omron® digital blood pressure monitor 9.2. Body mass index (BMI) assessed by body weight (measured using a digital weighing scale BC-545, Tanita, USA) and body height (measured using a stadiometer) using the formula BMI = weight (kg) / (standing height (meters) squared) 9.3. Percentage body fat, assessed using bioelectrical impedance analysis using a digital weighing scale (BC-545) 9.4. Waist circumference, assessed using flexible tape at the natural waist 9.5. Total/LDL/HDL cholesterol, triglycerides and HbA1c, assessed using antecubital vein blood test	—

Measure

Time frame

The following will be assessed at the baseline (1-2 weeks after hospitalisation), 6 weeks after hospitalisation and at the follow-up (12 months after hospitalisation): 1. Self-reported physical activity, assessed using the Simple Physical Activity Questionnaire (SIMPAQ) 2. Cardiorespiratory fitness, assessed using the Åstrand indirect test of maximal oxygen uptake (VO2max) 3. Autonomic function, assessed using electrocardiography (ECG) 4. Cognitive and social determinants of exercise, assessed using various validated questionnaires: 4.1. 1-item proxy for perceived fitness 4.2. 3 items regarding exercise-related self-efficacy 4.3. 16 items regarding exercise-related outcome expectancies 4.4. 1 item regarding exercise intention 4.5. 12 item SSK-Scale for self-concordance 4.6. 10 items regarding action and coping planning 4.7. 19 items regarding perceived exercise barriers 4.8. 7 items regarding exercise-related social support 5. Depression severity, assessed using: 5.1. Hamilton Rating Scale for Depression 17-item (HAMD17) 5.2. Beck Depression Inventory (BDI) 6. Self-perceived physical and psychological health, assessed using the Medical Outcomes Study 12-item Short Form Health Survey (SF-12) 7. Insomnia symptoms, assessed using the 7-item Insomnia Severity Index (ISI) 8. Cognitive function, assessed using the Test of Attentional Performance 9. Cardiovascular health risk markers: 9.1. Blood pressure, assessed using an Omron® digital blood pressure monitor 9.2. Body mass index (BMI) assessed by body weight (measured using a digital weighing scale BC-545, Tanita, USA) and body height (measured using a stadiometer) using the formula BMI = weight (kg) / (standing height (meters) squared) 9.3. Percentage body fat, assessed using bioelectrical impedance analysis using a digital weighing scale (BC-545) 9.4. Waist circumference, assessed using flexible tape at the natural waist 9.5. Total/LDL/HDL cholesterol, triglycerides and HbA1c, assessed using antecubital vein blood test

—

Countries

Switzerland

Outcome results

None listed